- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1985
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk ; volume:29 ; number:4 ; day:27 ; month:6 ; year:2022 ; pages:327-336 ; date:7.2022
High blood pressure & cardiovascular prevention ; 29, Heft 4 (27.6.2022), 327-336, 7.2022
- Creator
-
Figorilli, Filippo
Mannarino, Massimo R.
Bianconi, Vanessa
Pirro, Matteo
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40292-022-00529-2
- URN
-
urn:nbn:de:101:1-2022082923434262981401
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Figorilli, Filippo
- Mannarino, Massimo R.
- Bianconi, Vanessa
- Pirro, Matteo
- SpringerLink (Online service)
Other Objects (12)
Cholesterol-Lowering Super juice
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study
Cholesterol lowering: role in cancer prevention and treatment
Cholesterol lowering effect of a soy drink enriched with plant sterols in a French population with moderate hypercholesterolemia
Low-density lipoprotein cholesterol lowering treatment: the current approach
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline
Short-term LDL cholesterol-lowering efficacy of plant stanol esters
Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis
Cholesterol-Lowering Super juice
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study
Cholesterol lowering: role in cancer prevention and treatment
Cholesterol lowering effect of a soy drink enriched with plant sterols in a French population with moderate hypercholesterolemia
Low-density lipoprotein cholesterol lowering treatment: the current approach
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline
Short-term LDL cholesterol-lowering efficacy of plant stanol esters
Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis
Cholesterol-Lowering Super juice
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study
Cholesterol lowering: role in cancer prevention and treatment
Cholesterol lowering effect of a soy drink enriched with plant sterols in a French population with moderate hypercholesterolemia
Low-density lipoprotein cholesterol lowering treatment: the current approach
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline
Short-term LDL cholesterol-lowering efficacy of plant stanol esters
Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?